Cardiovascular diseases (CVD) are a leading cause of morbidity and mortality worldwide. Preventative and therapeutic strategies focused on controlling traditional risk factors have not always been successful. Recently, the use of miRNAs as novel biomarkers in CVD has opened up new possibilities for discovering novel therapeutic targets and understanding CVD development. To date, the total number of miRNAs encoded in the human genome surpasses 1,000.
In this 2-part webinar series, the first part will focus on qPCR technology and associated challenges and solutions. The second part will cover why and how microRNAs are being investigated as biomarkers for CVD, as well as examine some recent findings in the field. Join us to find out how scientists are investigating the role of noncoding RNA in CVD and how you can get started in your lab!
Save your spot for the live presentation and take this opportunity to get your questions answered by the experts.
2-part webinar series: Introduction to qPCR and RNAs as biomarkers in cardiovascular diseases – a case study
Part 1: Introduction to real-time PCR (q-PCR/qPCR/qRT-PCR)
April 11, 9:30 a.m. EDT, 2:30 pm. GMT, 3:30 p.m. CEST
Speaker: Dr. Vishwadeepak Tripathi, Global Marketing Manager – QIAGEN
Part 2: Noncoding RNAs in cardiovascular disease – potential as biomarkers and more
April 18, 9:30 am EDT, 2:30 pm GMT, 3:30 pm CEST
Speaker: Dr. Allison Bierly, Global Market Manager – QIAGEN
Join now: https://attendee.gotowebinar.com/register/4412009590655294466
Scheduling conflict? Don’t worry! Register now and you’ll receive a link to view an on-demand recording after the event.
We look forward to addressing the challenges you face in qPCR technology and miRNA expression profiling as biomarkers in your cardiovascular disease research.